-+ 0.00%
-+ 0.00%
-+ 0.00%

iBio names endocrinologist Molly Carr as chief medical officer

PUBT·08/04/2026 11:06:58
Listen to the news
iBio names endocrinologist Molly Carr as chief medical officer
  • iBio named endocrinologist Molly Carr as chief medical officer to lead global clinical strategy, medical affairs, regulatory work for its cardiometabolic pipeline.
  • Carr most recently served as clinical head, associate vice president of Eli Lilly’s Insulin and Glucagon Franchise, overseeing the Phase 3 efsitora program.
  • Her prior roles included senior positions at GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University, the University of Washington.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040700PRIMZONEFULLFEED9802906) on August 04, 2026, and is solely responsible for the information contained therein.